Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chavez

Showing results (211-220 of 285) with videos related to

Pageof 29
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 20, 2019
Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanomaC A Castaneda, M Castillo, C Torres-Cabala, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Annals of Hepatology|September 14, 2011
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver diseaseAlberto Espino, Andrea Villagrán, Valeska Vollrath, et al.
Pageof 29

Showing results (211-220 of 285) with videos related to

Sort By:
Pageof 29
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 20, 2019
Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanomaC A Castaneda, M Castillo, C Torres-Cabala, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Annals of Hepatology|September 14, 2011
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver diseaseAlberto Espino, Andrea Villagrán, Valeska Vollrath, et al.
Pageof 29